Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 132.48% | 123.76% | 127.23% | -14.52% | -15.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.07% | 27.30% | 22.20% | -19.48% | -15.87% |
| Operating Income | -29.07% | -27.30% | -22.20% | 19.48% | 15.87% |
| Income Before Tax | 7.46% | 3.41% | -27.28% | -21.95% | -28.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.46% | 1.88% | -32.72% | -30.34% | -39.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.46% | 1.88% | -32.72% | -30.34% | -39.80% |
| EBIT | -29.07% | -27.30% | -22.20% | 19.48% | 15.87% |
| EBITDA | -29.44% | -27.71% | -22.52% | 19.52% | 15.98% |
| EPS Basic | 84.97% | 83.29% | 61.80% | 28.17% | 7.00% |
| Normalized Basic EPS | 78.45% | 78.44% | 69.90% | 59.88% | 43.17% |
| EPS Diluted | 84.97% | 83.29% | 61.80% | 28.17% | 7.00% |
| Normalized Diluted EPS | 78.45% | 78.44% | 69.90% | 59.88% | 43.17% |
| Average Basic Shares Outstanding | 799.76% | 571.08% | 376.34% | 181.70% | 109.17% |
| Average Diluted Shares Outstanding | 799.76% | 571.08% | 376.34% | 181.70% | 109.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |